Lumosa scientist spoke at 2017 International Stroke Conference

Lumosa Therapeutics Co., Ltd. (Lumosa, 6535.TWO) announced the preclinical study results of its drug candidate for the treatment of acute ischemic stroke at the International Stroke Conference 2017 (ISC).

Naldebain® draws attention at Taiwan Society of Colon and Rectal Surgeions

Dr. Chien-Yuh Yeh was invited to report the phase 3 trial results of Naldebain® (dinalbuphine sebacate) I.M. Injection (also called LT1001) at the Annual Meeting of Taiwanese Society of Colon and Rectal Surgeons held in Kaohsiung, Taiwan on December 10, 2016.  The Society celebrated its 30th anniversary since inception.  Speaker Dr. Yeh is a practicing surgeon at Chang Gung Memorial Hospital and one of the lead investigators of this phase 3 trial. The title of his presentation was “A Phase III Trial of a Novel Long Acting Painkiller,” which highlighted the unique safety and long-lasting efficacy profile of the product. 

Lumosa presents LT3001 at the stroke forum

Taiwan Stroke Society held its 2016 Annual Meeting and the inaugural “Asia Pacific Stroke Forum" (hereafter referred to as “the Forum”) on November 12 and 13 in The Grand Hotel, Taipei. Stroke specialists and key opinion leaders all over the world were invited to discuss the newest stroke treatment methods. Dr. Sheng-Wen Yeh of Lumosa Therapeutics (Lumosa, TPEx:6535) was invited to give an orally presentation on the findings in a recent non-primate study of LT3001, a novel chemical entity under development by Lumosa for the treatment of acute ischemic stroke.

Lumosa Presents LT3001 at the thrombolysis thrombectomy and acute stroke therapy symposium

Dr. Mimi Yeh of Lumosa Therapeutics (Lumosa) presented the recent advancement in the preclinical research of LT3001 in the oral session at the 13th International Symposium on Thrombolysis Thrombectomy and Acute Stroke Therapy (TTST), held in Kobe, Japan (October 30th and November 1, 2016).  TTST is one of the few international medical conferences focusing on stroke research. Lumosa was honored to be the only drug development company invited to present and the presentation titled “Study of a novel small molecule, LT3001, in a thromboembolic stroke model in non-human primates"

Lumosa is public traded on Taipei Exchange (6535.TWO)

Lumosa Therapeutics Co., Ltd., (Lumosa) is listed on the Emerging Stock Board in Taipei Exchange, Symbol 6535, on September 26, 2016. Lumosa is dedicated to new drug development for the treatment of CNS and inflammatory diseases using reSEARCH & DEVELOPMENT model. One of its pipeline, LT1001, is a week-long acting analgesic injection that is awaiting new drug approval from Taiwan FDA. The other, LT3001, is a novel treatment for acute ischemic stroke.

LT1001 clinical results accepted by the Clinical Journal of Pain

After successful execution of the license agreement with Syntano Technology Venture for China in June, Lumosa Therapeutics Co., Ltd. (TPEx 6535), receives a notification from “the Clinical Journal of Pain” (CJP) that the manuscript on LT1001 Phase III trial results was accepted for publication. “The Clinical Journal of Pain” is an esteemed international journal ranked among top 10 of clinical journals in analgesic and anesthetic field. It publishes many medical articles addressing pain management in clinical setting and new treatment models etc. for the past 30 years. The acceptance by CJP indicated LT1001 is regarded as an innovative product in clinical pain management, which deserves the recognition by international medical experts.